Rex Bionics plc and Deltason establish partnership to commercialise the REX Robot in Hong Kong

22 April 2015. Link here.

Rex Bionics plc, the pioneer of the REX Robot technology that enhances the mobility of wheelchair users and Deltason Medical Ltd, a distributor of rehabilitation equipment in Hong Kong and China, are pleased to announce that they have signed a distribution agreement in which Deltason will exclusively represent REX in Hong Kong, both in neuro-rehabilitation clinics and in the personal use market.

Deltason will launch REX at the Hong Kong International Medical Devices and Supplies Fair (May 18-20 2015.)

Based on data from the World Health Organisation, the Company estimates that more than 2,000 Hong Kong citizens live with a spinal cord injury.1

Crispin Simon, Chief Executive, Rex Bionics plc said: “We are delighted with our partnership with Deltason. Hong Kong is an important market – both in itself and for the leadership of its leading clinicians and researchers – and Deltason has an excellent reputation for service and innovation; as well as long-standing relationships in the rehabilitation community.”

“We are in discussion with distribution partners of a similar quality in other countries and plan to establish coverage in other important markets over the next 24 months.

Tommy Chan, Director, Deltason Medical Ltd said: “We are very pleased to have been chosen as REX’s representative in Hong Kong and believe that there is a great opportunity here for this exciting technology.”

For further information please contact:

Rex Bionics Plc
Crispin Simon, Chief Executive Officer
+44 (0) 748 3 167851
Peter Worrall, Chief Financial Officer
+44 (0) 142 864 5416

Stifel Nicolaus Europe Limited (NOMAD and Broker)
Jonathan Senior/Giles Balleny
+44 (0) 20 7710 7600

Consilium Strategic Communications
Mary-Jane Elliott / Jessica Hodgson / Chris Welsh / Lindsey Neville
+44 (0) 203 709 5700

About Deltason
Deltason Medical Limited is a 20-year old, well established distributor of rehabilitation equipment in Hong Kong, China and has a strong presence in neurology and stroke rehabilitation. Deltason is headquartered in Hong Kong, China with approximately 80 employees, a sub branch office at Beijing, 30 direct sales representatives and over 30 local sub-dealers throughout mainland China. Deltason is the distributor for more than 30 rehabilitation product lines developed by some of the global industry leaders, and focuses on marketing innovative products to healthcare professionals who demand superior quality. Over the years, Deltason has established a reputation of rigorous quality, unique products, profound knowledge and excellent customer service.

About Rex Bionics
Rex Bionics (AIM: RXB) is the UK AIM-listed pioneer of the REX Robot that enhances the mobility of wheel-chair users. Founded in Auckland, New Zealand by two robotics engineers with first-hand experience of wheelchair users and their needs, Rex Bionics is working with physiotherapists to develop the practice of Robot-Assisted Physiotherapy (RAP). In a session of RAP, REX lifts patients from a sitting position into a robot-supported standing position, allowing them to take part in a set of supported walking and stretching exercises, designed by specialist physiotherapists.

Wheelchair users are at risk of developing numerous medical complications from extended periods of sitting. By enabling them to spend more time standing, walking and exercising, REX may offer significant health benefits, including improved sleep, cardiovascular performance, maintenance of joint range, and a reduction in common abdominal problems and prescription drug use. A programme of clinical trials is now under way to evaluate these potential benefits.

REX can be used by people with complete spinal cord injury, as well as people who have suffered a stroke or other traumatic brain injury; and people with multiple sclerosis and muscular dystrophy. REX P, for use in the home, enables users to walk and stand with their hands free – providing more work and recreation options.
In May 2014, Rex Bionics joined AIM with a fundraising of £10 million (gross) to scale up production, distribution and marketing internationally, in order to support growing demand for both REX products as well as developing the next generation of REX devices, REX 3.

REX is not approved for At-Home use in the United States of America.

1. World Health Organisation: International Perspectives on Spinal Injury, 2013.